KÄÄPÄ Biotech has announced the successful closing of a €9m strategic investment.
This major milestone underscores the company’s market-leading position and highlights the ambitious growth plans in the global nutraceutical market.
The funding round was led by PeakBridge, a global agri-food tech fund manager and member of the Edmond de Rothschild Private Equity partnership, together with Zintinus, a Food Tech sector venture capital fund.
KÄÄPÄ Biotech is a biotechnology company specialised in researching, innovating, developing, producing and selling functional mushroom products.
In September 2024, it unveiled its state-of-the-art mushroom cultivation facility in Paimio, Finland and in June 2025, the company opened another cultivation facility in Salo, Finland.
This strategic investment will accelerate KÄÄPÄ Biotech’s mission to bring premium, traceable and clinically validated NordRelease functional mushroom ingredients to the forefront of global wellness and health.
The funding will boost production capacity, deepen vertical integration, scale operations and strengthen the global position of its NordRelease ingredients to meet rising international demand.
“The functional mushroom market continues to expand rapidly, with the sector fuelled by increasing customer demand for high-quality, trustworthy and science-backed functional mushroom products," said Eric Puro, CEO and co-founder of KÄÄPÄ Biotech.
"We are honoured that more than 180 companies across more than 20 markets trust us as their preferred partner."
“This strategic investment from both PeakBridge and Zintinus represents a strong vote of confidence in our vision, technology and team."
"We are overjoyed by the strengthening relationship with PeakBridge, who invested in us earlier this year."
"In addition to the strategic partnership and funding, PeakBridge’s tailored value-add programmes for portfolio companies are a cornerstone of their partnership approach, guided by a team with deep food industry expertise."
"We are equally grateful for the valuable funding, strategic connections and industry expertise that Zintinus contributes to our ongoing growth."
"This investment marks a major milestone as we continue scaling our operations to meet global demand while leading innovation in mushroom biotech.”
"KÄÄPÄ Biotech exemplifies what we look for in this space: vertical integration that addresses real supply chain vulnerabilities, rigorous bioactive standardisation and a European base that cuts dependence on Asia's concentrated production," added Dr Gali Artzi, Partner & CTO at PeakBridge.
"Functional mushrooms represent more than a wellness trend; they're a convergence of centuries of traditional use, growing clinical evidence and modern extraction science that delivers measurable health benefits."
"KÄÄPÄ is a true sector leader and we're thrilled to expand our support into this next chapter."
"We are pleased to support KÄÄPÄ Biotech at a pivotal moment for the functional mushroom industry, which is projected to grow rapidly as global demand for science-backed, high-quality functional foods and beverages continues to rise," said Christian Neuss, Partner at Zintinus.
"Through its proprietary NordRelease extraction process, clinically validated functional mushroom ingredients and scalable indoor cultivation, KÄÄPÄ Biotech is defining the future of this market and continues to lead its evolution."
"Their commitment to transparent production and vertical integration aligns closely with Zintinus’ mission to support transformative food technologies."
"This strategic partnership enables us to accelerate their next phase of growth and create long-term value for consumers, the environment and investors."